Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report

Hidefumi Koiwai, Mikio Kamimura, Jun Takahashi, Yukio Nakamura, and Hiroyuki Kato

Abstract

Background: Osteoporosis is a serious disease that causes bone fragility fractures and increases mortality. Bisphosphonates are the first-line drugs for osteoporosis. However, the gains in bone mineral density by use of bisphosphonates alone are limited.

Case presentation: We describe the clinical outcome of a Japanese woman with osteoporosis treated with bisphosphonates after multiple spinal fractures. After 3 years of treatment with the bisphosphonate alendronate, her lumbar bone mineral density and bilateral hip bone mineral density markedly increased by 61.9% and 32.5%, respectively.

Conclusion: We considered that our patient’s multiple fractures had caused a decrease in bone mineral density, which naturally improved with fracture healing to enhance the increase in bone mineral density with bisphosphonate treatment.

Keywords: Bone mineral density, Bisphosphonate, Osteoporosis, Spinal fracture

Introduction

Osteoporosis (OP) is a serious and widespread disease that predisposes patients to bone fragility fractures and increases mortality. Bisphosphonates (BPs) are the first-line drugs for OP treatment to increase bone mineral density (BMD) and prevent fractures [1, 2]. However, the improvements in BMD by BPs alone are limited and gradually diminish after the first few years [3, 4]. Bone et al. observed that alendronate (ALN) provided increases of 13.8% in lumbar spine BMD (L-BMD) and 7.8% in total hip BMD (H-BMD) during 10 years [4]. Compared with BPs, teriparatide (TPTD) (parathyroid hormone 1–34) has stronger effects on L-BMD increase and inhibition of spinal fractures [5]. Therefore, TPTD may be preferential for patients with OP who have greatly diminished BMD and/or multiple bone fractures. We recently encountered a rare case of a patient with OP in whom BMD increased remarkably with BP treatment only.

Case presentation

Our patient was a 59-year-old Japanese woman 49 kg in weight and 153.2 cm in height. Her chief complaint upon presentation was severe back pain. She reported having a total of five episodes of strong acute back pain in the previous year. At the first visit, her L-BMD was 0.572 g/cm2 (−4.5 standard deviation [SD]), and her H-BMD was 0.671 g/cm2 (−2.2 SD). Spinal radiographs showed five vertebral compression fractures. Bone turnover markers (BTMs) were highly increased (Table 1). Bone scintigraphy revealed high accumulation at one lumbar vertebra and one thoracic vertebra, with diffuse mild uptake throughout the entire spine.

She was diagnosed with OP in accordance with the revised criteria established by the Japanese Society for Bone and Mineral Research [6]. Because daily TPTD was not possible, owing to her living abroad, ALN 35 mg/week was prescribed until her planned return.
month later, her back pain was relieved, and she returned home. At 4 months of ALN, L-BMD and H-BMD were greatly increased by 29.5% and 18.3%, respectively (Figs. 1, 2). Hence, ALN treatment was continued.

The patient’s BTMs began to decrease soon after therapy commencement (Table 1). During 2 years of treatment, the patient’s urinary N-terminal telopeptide of type I collagen (NTX) decreased by 95.6% and serum bone alkaline phosphatase (BAP) fell by 85.6%. At 3 years of ALN monotherapy, L-BMD and H-BMD were markedly increased by 61.9% and 32.5%, respectively (Figs. 1, 2), which remained high over a treatment period of 6.5 years.

The present report was approved by the Institutional Ethics Committee at Shinshu University School of Medicine. The patient gave written informed consent for publication of her personal medical information prior to the start of treatment.

Table 1 Changes in laboratory values during bisphosphonate therapy

|                      | Pretreatment | 2 Months | 4 Months | 24 Months |
|----------------------|--------------|-----------|----------|-----------|
| ALP (U/L)            | 827          | 753       | 367      | 197       |
| NTX (nmol BCE/mmol Cr) | 313.5        | 98        | 31.3     | 13.9      |
| BAP (μg/L)           | 90.5         | 94.7      | 32.3     | 12.7      |

ALP Alkaline phosphatase, BAP Bone alkaline phosphatase, BCE Bone collagen equivalents, Cr Creatinine, NTX Urinary N-terminal telopeptide of type I collagen

Discussion
After the first vertebral fracture, the risk of subsequent fractures increases greatly and may occur consecutively in a so-called vertebral fracture cascade [7]. The patient had experienced severe acute back pain five times throughout the year preceding treatment. Spinal radiographs confirmed five vertebral compression fractures, indicating the occurrence of a fracture cascade.

BTMs are normally increased during the fracture-healing process [8, 9]. At the first visit, our patient’s BTMs were extremely high (BAP, 90.5 μg/L; NTX, 313.5 nmol bone collagen equivalents/mmol Cr). However, they soon decreased after treatment commencement and were within reference values 2 years later. Thus, the BTMs might have been greatly increased by the vertebral fractures and then improved both from fracture healing and from ALN.

The effects of BPs on BMD are potent but limited. In a phase III study in Japan, the increases of L-BMD were 6.2% for ALN 5 mg/day [10] and 4.9% for risedronate 2.5 mg/day [11] at 48 weeks. L-BMD was also increased by 9.2% at 3 years of treatment with ALN 5 mg/day [12]. In our patient’s case, BMD increased remarkably with ALN alone during 3 years (L-BMD, 61.9%; H-BMD, 32.5%). This rate of increase is unexpected and supports
an additional mechanism of BMD improvement, such as the natural healing of the fracture cascade.

We previously reported two cases of pregnancy- and lactation-associated OP with multiple vertebral fractures [13]. In both patients, BMD gains with vitamins D and K treatment were impressive at 36.1% at 4 years in the first patient and 26.3% at 3 years in the second. In a recently encountered patient with anorexia nervosa, BTMs were highly increased by multiple vertebral fractures [14]. Treatment using a vitamin D analogue alone achieved remarkable L-BMD and H-BMD gains of 70.7% and 41.4%, respectively, at 8 months, although BMD improvement by vitamin D and/or K is usually very small. Similarly, in the present case, BMD increased markedly with BP monotherapy, with L-BMD gains of 29.5% at 4 months and 48.9% at 1 year. Results such as these seem possible only with simultaneous healing of fractures.

The common point in the above reports is the benefit of OP treatment after multiple fractures. On the basis of our findings, it was considered that multiple fractures might have caused decreases in BMD, which might be naturally improved by fracture healing to enhance the effects of OP treatment.

Limitations
The lack of serum 25(OH)D₃ data is a major limitation of this study. We have previously reported that 4 months of BP therapy significantly decreased 25(OH)D₃ and that 3-year BP therapy without vitamin D supplementation significantly increased 25(OH)D₃ [15, 16]. However, in our patient’s case, BMD rapidly increased; thus, we speculated that 25(OH)D₃ levels might not have had an obvious influence on the results in this study. Another limitation of the present study includes its retrospective design. Nonetheless, our case report provides evidence of a good response in BMD after BP treatment in a patient with multiple fractures.

Conclusions
We report a rare case, that of a 59-year-old woman with OP in whom BMD increased remarkably with BP treatment only. This case report reveals that multiple fractures might have caused decreases in BMD, which were naturally improved by fracture healing to enhance the effects of OP treatment.

Acknowledgements
Not applicable.

Authors’ contributions
YN and MK directed and designed this study. HK, MK, and YN wrote the main text. JT and HK gave suggestions on the study. All authors read and approved the final manuscript.

Funding
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.
Author details

1Koiwai Orthopedic Clinic, Mikageshinden 1585-4, Komoro 384-0091, Japan. 2Center of Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic, Kotobuki 595-17, Matsumoto 390-0021, Japan. 3Department of Orthopaedic Surgery, Showa-Inan General Hospital, Akaho 3230, Komagane 399-4117, Japan.

Received: 22 May 2019 Accepted: 5 August 2019

References

1. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.

2. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983–91.

3. Kamimura M, Nakamura S, Uchiyama S, Kato H. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int. 2017;28(2):559–66.

4. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate phase III osteoporosis treatment study group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.

5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporos. N Engl J Med. 2001;344:1434–41.

6. Orimo H, Kamimura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujisawa S. Japanese 2011 guidelines for prevention and treatment of osteoporosis: executive summary. Arch Osteoporos. 2012;7:20.

7. Briggs AM, Greig AM, Wark JD. The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int. 2007;18:575–84.

8. Nakagawa H, Kamimura M, Takahara K, Hashidate H, Kawaguchi A, Uchiyama S, Miyakata T. Changes in total alkaline phosphatase level after hip fracture: comparison between femoral neck and trochanter fracture. J Orthop Sci. 2006;11:135–59.

9. Takahara K, Kamimura M, Nakagawa H, Uchiyama S. Changes in biochemical markers of bone in patients with insufficiency fractures. J Bone Miner Metab. 2002;20:18–25.

10. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H. Risedronate Phase III Osteoporosis Treatment Research Group. A double-masked multicenter comparative study between alendronate and alfalcacido in Japanese patients with osteoporosis. Osteoporos Int. 1999;10:183–92.

11. Fujinaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H. Risedronate Phase III Research Group. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int. 2002;13:971–9.

12. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004;22:462–8.

13. Nakamura Y, Kamimura M, Ikekami S, Mukaiyama K, Komatsu M, Uchiyama S, Kato H. A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature. Ther Clin Risk Manag. 2015;11:1361–5.

14. Nakamura Y, Kamimura M, Koiwai H, Kato H. Adequate nutrition status important for bone mineral density improvement in a patient with anorexia nervosa. Ther Clin Risk Manag. 2018;14:945–948.

15. Kamimura M, Uchiyama S, Nakamura Y, Mukaiyama K, Ikekami S, Kato H. Short-term bisphosphonate treatment reduced the 25(OH)vitamin D3 level, and changed the values of parathyroid hormone, pentosidine, and bone metabolic markers by short-term bisphosphonate treatment. Ther Clin Risk Manag. 2017;13:161–8.